Affymax (AFFY) Posts Q3 Loss of $0.97, Narrower than Expected
More News related to AFFY
- Affymax (AFFY) Closes Stock Offering, Receiving Net Proceeds of $80M
- Affymax Announces Close of Common Stock Offering and Exercise of Underwriters' Overallotment Option
- Affymax (AFFY) Prices 4.1M Shares at $18.25/Share
- Affymax Prices Public Offering of Common Stock
- After-Hours Movers 11/18: DCI, CYBX, LTD Higher; JACK, NMM, AFFY, HOTT, SMTC, MVIS Lower
More News related to Earnings
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
Affymax, Inc. (NASDAQ: AFFY) reports Q3 loss of $0.97, versus the analyst estimate of ($1.23). Revenue for the quarter was $29.16 million, which compares to the estimate of $26.10 million.
Related Categories
EarningsStocks Mentioned
+0.47Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
